The authors of this Review discuss the current evidence suggesting that pathological immune activation contributes to irritable bowel syndrome (IBS). They explain how immune mediators can contribute to pain signalling and abdominal pain, and highlight the potential for targeting immune pathways in IBS.
- Javier Aguilera-Lizarraga
- Hind Hussein
- Guy E. Boeckxstaens
